Elutia Inc. Class A Common Stock (ELUT)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with business quality and financial staying power. Elutia is a commercial-stage medical device company with just 25 employees. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $2.4M and a net loss of $7.6M, or diluted EPS of -$0.17. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $3.1M and net loss was $7.5M. Full-year fiscal 2025, period ended 2025-12-31, showed revenue of $12.3M and net income of $53.4M, but fiscal 2024, period ended 2024-12-31, had revenue of $14.5M and a net loss of $53.9M; fiscal 2023, period ended 2023-12-31, had revenue of $24.7M and a net loss of $37.7M. Sales have shrunk, and the recent quarters are deeply unprofitable. The Lynch category is TURNAROUND, returned to profit after a loss within the last three years, but the latest filings show losses again. FairStock's Piotroski score is 1/9 and Altman Z-score is -5.35, signs of distress. Trailing free cash flow is -$46.0M, a -134.6% FCF yield against the $34.2M market cap at the 2026-10-13 close. FairStock's data show debt-to-equity of 0.28, ROCE of -34.66%, P/B of 2.15, and P/E of -1.21 at that close. I see no clear moat: a tiny surgical biomatrix firm with $2.4M quarterly revenue lacks pricing power against larger competitors. At $0.77, the market is pricing this as an option, not a Graham bargain. Without a reversal in cash burn and revenue, the margin of safety is absent.

In plain English: Elutia makes surgical products from tissue and drug-delivering implants, mainly for women's health and heart-related uses. The business is very small, is losing much more money than it brings in, and sales have recently fallen. At 77 cents per share, the stock looks like a risky turnaround bet rather than a clear bargain based on its current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer